Go Deep
Sagimet Biosciences Inc.
Sagimet Biosciences Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,515 | -6.3 | 2.21 | 0.01 | 759.96 |
| Oct 2026 | 19,765 | -5.9 | 2.09 | 0.01 | 716.38 |
| Oct 2026 | 19,405 | -6.8 | 2.26 | 0.01 | 775.83 |
| Oct 2026 | 19,492 | -6.3 | 2.22 | 0.01 | 759.61 |
| Oct 2026 | 19,008 | -7.0 | 2.45 | 0.01 | 840.07 |
| Oct 2026 | 18,501 | -7.7 | 2.70 | 0.01 | 923.51 |
| Oct 2026 | 18,357 | -7.9 | 2.77 | 0.01 | 944.88 |
| Oct 2026 | 18,380 | -7.8 | 2.75 | 0.01 | 939.19 |
Sagimet Biosciences Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -13,953,000.0 | -10,650,000.0 | -9,568,000.0 | -12,908,000.0 |
| EPS | -0.3 | -0.3 | -0.3 | -0.4 |
Sagimet Biosciences Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 2,000,000.0 | 0.0 | — |
| Net Profit | -51,038,000.0 | -45,567,000.0 | -27,876,000.0 | -30,499,000.0 | — |
| EPS | -1.6 | -1.4 | -2.7 | -1.4 | — |
Sagimet Biosciences Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 116,482,000.0 | 160,259,000.0 | 96,719,000.0 | 33,031,000.0 | — |
| Total Liabilities | 5,101,000.0 | 4,454,000.0 | 5,654,000.0 | 219,981,000.0 | — |
| Total Equity | 111,381,000.0 | 155,805,000.0 | 91,065,000.0 | -186,950,000.0 | — |
Owes vs Owns
Sagimet Biosciences Inc. owed $0.03 for every $1 it owned in Jun 2026, down from $6.66 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.03× | 0.04× | 0.03× | 0.06× | 6.66× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sagimet Biosciences Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 97.1%Other assets 2.8%
How it's funded — Dec 2025
Payables 1.1%Other liabilities 3.2%Shareholders' equity 95.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 113.1 | 151.2 | 94.9 | 32.3 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.1 | 0.1 | 0.1 | 0.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 7.4 | 0.0 | 0.0 |
| Other assets | 3.3 | 1.5 | 1.7 | 0.5 |
| Liabilities & equity | ||||
| Short-term debt | 0.1 | 0.1 | 0.1 | 0.1 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.1 |
| Payables | 1.3 | 1.4 | 0.2 | 1.1 |
| Other liabilities | 3.7 | 3.0 | 5.4 | 218.6 |
| Shareholders' equity | 111.4 | 155.8 | 91.1 | -186.9 |
| Net tangible assets | 111.4 | 155.8 | 91.1 | -186.9 |
Sagimet Biosciences Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -45,650,000.0 | -42,435,000.0 | -23,766,000.0 | -24,490,000.0 | — |
| Investing Activities | 4,556,000.0 | -61,683,000.0 | 12,580,000.0 | -32,010,000.0 | — |
| Financing Activities | 275,000.0 | 104,819,000.0 | 86,167,000.0 | -73,000.0 | — |